Clinical Trials Logo

Clinical Trial Summary

Aim of the work: 1. To compare conventional medical therapy versus catheter-directed therapy in intermediate high risk acute pulmonary embolism. 2. To define predictors of progression from intermediate to high-risk in medically-treated patients for ideal timing for intervention.


Clinical Trial Description

Based on history, physical examination, surface 12-lead ECG, bed-side echocardiography, patients with a high probability of acute pulmonary embolism are selected and subjected to CT pulmonary angiography to confirm the diagnosis and calculate the pulmonary artery obstruction score. Routine labs are withdrawn, including cardiac troponin.Methods: Detailed TTE will be done with emphasis on the following indicators of RV strain and/or dysfunction: 1. Echocardiography findings that are indicative of RV dysfunction - tricuspid annular plane systolic excursion (TAPSE) - S' Velocity - the McConnell's sign 2. RV dilation 3. interventricular septal flattening. 4. elevated right ventricular pressures 5. plethoric inferior vena cava 6. tricuspid regurgitation 7. Direct visualization of thromboembolic in the RT heart and PA 8. RV stroke volume measured by RVOT VTI. 9. LV stroke volume measured by LVOT VTI Intermediate-high risk patient will be identified (based on the calculated pulmonary embolism severity index, RV dysfunction on TTE and/or CT, cardiac troponin), and then randomized to either receiving conventional medical treatment or catheter-directed interventional therapy if the patient consents. 7. Catheter directed therapy A. Mechanical embolectomy: Mechanical fragmentation will be done using a 6 F pigtail catheter inserted inside the thrombus guided by the CTPA images. Hydro-mechanical defragmentation (HMD) is one of the CDT modalities for high-risk PE patients, in which rapid pigtail rotation is combined with heparinized saline injection for thrombus fragmentation.(4) B. Suction embolectomy: Suction embolectomy was one of the earliest techniques for transcatheter treatment of PE, and was introduced by Greenfield et al, using a 12-Fr catheter with a cup on its distal end. Suction was applied manually to the catheter hub with a large syringe. (13) The Penumbra Indigo aspiration system (Penumbra Inc., Alameda, CA, USA) that will be used, is an 8-Fr device and its associated tubing, pump, and separator, has the flexibility for placement in segmental branches of the pulmonary arteries. The Indigo aspiration system is indicated for use in the peripheral arterial system and the pulmonary arteries, receiving U.S. Food and Drug Administration 510(k) clearance for PE in December 2019.(14) C. Catheter directed thrombolysis: Catheter-directed thrombolysis allows delivery of the thrombolytic agent directly to the area of highest embolic burden via a catheter. Intermediate-high risk patient will be identified (based on the calculated pulmonary embolism severity index, RV dysfunction on TTE and/or CT, cardiac troponin), and then randomized to either receiving conventional medical treatment or catheter-directed interventional therapy if the patient consents. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05612854
Study type Interventional
Source Assiut University
Contact Shrouk K Ali, MSc
Phone +0201225134030
Email shrouk31@aun.edu.eg
Status Not yet recruiting
Phase Early Phase 1
Start date December 30, 2022
Completion date December 30, 2024

See also
  Status Clinical Trial Phase
Withdrawn NCT04996667 - Effect of iNO in Patients With Submassive and Massive PE Phase 2
Terminated NCT03988842 - Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism Phase 4
Not yet recruiting NCT06246045 - Artificial Intelligence to StrategiCally Enhance Pulmonary Embolism Response Team Activation N/A
Enrolling by invitation NCT04855370 - Non-Invasive Measurement of Cardiac Output and Stroke Volume in PE N/A